

Amendments to the Specification:

Please delete the first paragraph and replace it with the following: --This application is a divisional of United States Patent Application No. 09/904,065, filed July 12, 2001 and now United States Patent No. 6,682,892, which claims priority to United States Provisional Application Nos. 60/218,188, filed July 13, 2000, and 60/283,880, filed April 13, 2001.--

Response to Restriction Requirement

Claims 25 and 26 are currently pending in the application. In an Office Action, dated June 21, 2005, the Examiner has issued a Restriction Requirement and required election between:

- 1) Group I, comprising claim 25; and
- 2) Group II, comprising claim 26.

Furthermore, the Examiner has required the election of a single Sequence upon election of either Group I or II.


Applicants herein elect Group I, comprising claim 25, for prosecution on the merits. Furthermore, Applicants elect SEQ.ID.No. 1 for prosecution on the merits.

Applicants respectfully request consideration and allowance of the claims remaining herein.

Last, Applicants hereby petition for any required extension of time. Please charge all required fees to Deposit Account No. 500329.

Respectfully submitted,

Date: July 13, 2005



Jeffrey H. Tidwell
Attorney for Applicant
Registration No. 47,995

Agouron Pharmaceuticals, Inc./A Pfizer Company
Patent Department
10777 Science Center Drive
San Diego, California 92121
Phone: (858) 638-3877
Fax: (858) 678-8233